deerfield management

Deerfield Management’s Jim Flynn on CRISPR, and that $550M new fund

CRISPR gene editing technology is one of the most intriguing growth fields in biotech, says Deerfield Management president Jim Flynn. The venture firm just launched a new $550 million fund, and it'll focus on seeding startups and funding new companies - and is very interested in this space.

By Meghana Keshavan

Startups, BioPharma

Deerfield Management launches $550M biotech fund, has impressive investor base and will turn some profits over to charity

With an impressive roster of backers, Deerfield Management is kicking off a $550 million biotech fund. It will invest in cancer, genetic and orphan diseases - and donate some of its profits to charity.

By Meghana Keshavan

With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?

Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.